CRISPR Therapeutics priced $550 million of convertible senior notes due 2031 in a private offering to qualified institutional buyers. The transaction provides near-term financing but introduces potential equity dilution upon conversion and adds senior convertible debt to the capital structure. Pricing was announced Wednesday; no further terms were disclosed in the report.
CRISPR Therapeutics priced $550 million of convertible senior notes due 2031 in a private offering to qualified institutional buyers. The transaction provides near-term financing but introduces potential equity dilution upon conversion and adds senior convertible debt to the capital structure. Pricing was announced Wednesday; no further terms were disclosed in the report.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
